| 2026-05-22 |
详情>>
内部人交易：
Smith Michael Alexander股份减少6149.00股
|
| 2026-05-07 |
详情>>
股本变动：
变动后总股本21675.25万股
|
| 2026-05-07 |
详情>>
业绩披露：
2026年一季报每股收益-0.76美元,归母净利润-1.64亿美元,同比去年增长36.25%
|
| 2026-05-07 |
财报披露：
美东时间 2026-05-07 盘前发布财报
|
| 2026-04-08 |
复牌提示：
2026-04-07 16:00:10 停牌，复牌日期 2026-04-07 16:30:00
|
| 2026-04-01 |
股东大会：
将于2026-05-13召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors, Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D., to serve until the 2029 Annual Meeting of Shareholders;
2.To conduct an advisory vote on the 2025 compensation of our named executive officers (“NEOs”);
3.To ratify the appointment of Ernst & Young LLP (“Ernst & Young”) as our independent registered public accounting firm for the year ending December 31, 2026;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2026-02-19 |
详情>>
业绩披露：
2025年年报每股收益-6.42美元,归母净利润-12.77亿美元,同比去年增长-39.73%
|
| 2026-02-19 |
详情>>
业绩披露：
2023年年报每股收益-5.34美元,归母净利润-7.5亿美元,同比去年增长-55.66%
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-4.89美元,归母净利润-9.48亿美元,同比去年增长-39.82%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-3.12美元,归母净利润-5.78亿美元,同比去年增长-26.34%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-1.42美元,归母净利润-2.57亿美元,同比去年增长-63.33%
|
| 2025-04-04 |
股东大会：
将于2025-05-15召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors, Leo Lee and William H. Lewis, to serve until the 2028 Annual Meeting of Shareholders;
2.To conduct an advisory vote on the 2024 compensation of our named executive officers (“NEOs”);
3.To ratify the appointment of Ernst & Young LLP (“Ernst & Young”) as our independent registered public accounting firm for the year ending December 31, 2025;
4.To approve Amendment No. 2 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-02-20 |
详情>>
业绩披露：
2022年年报每股收益-3.91美元,归母净利润-4.82亿美元,同比去年增长-10.79%
|
| 2025-02-20 |
详情>>
业绩披露：
2024年年报每股收益-5.57美元,归母净利润-9.14亿美元,同比去年增长-21.91%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-4.27美元,归母净利润-6.78亿美元,同比去年增长-20.36%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-3.02美元,归母净利润-4.58亿美元,同比去年增长-13.13%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-1.06美元,归母净利润-1.57亿美元,同比去年增长1.67%
|
| 2024-04-01 |
股东大会：
将于2024-05-13召开股东大会
会议内容 ▼▲
- 1.To elect four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders;
2.To conduct an advisory vote on the 2023 compensation of our named executive officers (“NEOs”);
3.To ratify the appointment of Ernst & Young LLP (“Ernst & Young”) as our independent registered public accounting firm for the year ending December 31, 2024;
4.To approve Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2023-03-31 |
股东大会：
将于2023-05-11召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors, Elizabeth McKee Anderson, Clarissa Desjardins, Ph.D., and David W.J. McGirr, to serve until the 2026 Annual Meeting of Shareholders;
2.To conduct an advisory vote on the 2022 compensation of our named executive officers (“NEOs”);
3.To conduct an advisory vote on the frequency of future shareholder advisory votes on the compensation of our NEOs;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023;
5.To approve the Insmed Incorporated Amended and Restated 2019 Incentive Plan;
6.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-01 |
股东大会：
将于2022-05-11召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors, Alfred F. Altomari and William H. Lewis, to serve until the 2025 Annual Meeting of Shareholders;
2.To conduct an advisory vote on the 2021 compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2022;
4.To approve an amendment to the Insmed Incorporated 2019 Incentive Plan;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-03-31 |
股东大会：
将于2020-05-12召开股东大会
会议内容 ▼▲
- 1.election of three Class II directors, Clarissa Desjardins, Ph.D., David W.J. McGirr, and Elizabeth McKee Anderson, to serve until the 2023 Annual Meeting of Shareholders;
2.an advisory vote on the 2019 compensation of our named executive officers;
3.ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020;
4.approval of an amendment to the Insmed Incorporated 2019 Incentive Plan;
5.transaction of such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-04-04 |
股东大会：
将于2019-05-16召开股东大会
会议内容 ▼▲
- 1.election of three Class I directors, Alfred F. Altomari, Steinar J. Engelsen, M.D., and William H. Lewis, to serve until the 2022 Annual Meeting of Shareholders;
2.an advisory vote on the 2018 compensation of our named executive officers;
3.ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019;
4.approval of the Insmed Incorporated 2019 Incentive Plan;
5.transaction of such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2018-04-05 |
股东大会：
将于2018-05-15召开股东大会
会议内容 ▼▲
- 1.election of two Class III directors, David R. Brennan and Melvin Sharoky, M.D., to serve until the 2021 Annual Meeting of Shareholders;
2.an advisory vote on the 2017 compensation of our named executive officers;
3.ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018;
4.approval of the Insmed Incorporated 2018 Employee Stock Purchase Plan;
5.transaction of such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-07 |
股东大会：
将于2017-05-18召开股东大会
会议内容 ▼▲
- 1.elect three Class II directors, Donald Hayden, Jr., David W.J. McGirr and Myrtle Potter, to serve until the 2020 Annual Meeting of Shareholders;
2.conduct an advisory vote on the compensation of our named executive officers;
3.conduct an advisory vote on the frequency of future shareholder advisory votes on the compensation of our named executive officers;
4.ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2017;
5.approve the Insmed Incorporated 2017 Incentive Plan;
6.transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|